Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Proline Henagliflozin in Chinese Subjects with Varying Degrees of Liver Dysfunction

• Published in: Journal of clinical pharmacology Vol. 64; no. 8; p. 1015
• Main Authors: Ding, Likun, Yang, Lin, Ren, Danjun, Gao, Xiaohua, Zhang, Juanli, Liu, Meiyou, Sun, Li, Diao, Qingbo, Feng, Sheng, Wen, Aidong, Wang, Jingwen
• Format: Journal Article
• Language: English
• Published: England 01.08.2024
• Subjects: Adult; Area Under Curve; Asian People; Bridged Bicyclo Compounds, Heterocyclic - adverse effects; Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Diabetes Mellitus, Type 2 - drug therapy; East Asian People; Female; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Liver Diseases - metabolism; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - pharmacokinetics; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Young Adult; pharmacokinetics; type 2 diabetes mellitus; proline henagliflozin; liver dysfunction; pharmacodynamics; safety
• ISSN: 1552-4604
• DOI: 10.1002/jcph.2437

Proline henagliflozin, a novel selective inhibitor of sodium glucose cotransporter 2, is a treatment for type 2 diabetes mellitus. We designed a parallel-group, open-label, and multicenter study to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of henagliflozin in Chine...